March 21, 2022 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by CTI BioPharma Corp. as a specialty pharmacy provider for VONJOTM (pacritinib) for the treatment of intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L.
VONJO, approved by the U.S. Food and Drug Administration (FDA) on February 28, 2022, is a kinase inhibitor indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L.
This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
“Patients with severe thrombocytopenia have a poor prognosis with greater disease burden and shorter overall survival,” said Ela Lourido, vice president of Biopharma Services at Biologics. “We are honored to be chosen by CTI BioPharma to bring a new treatment option to these patients.”
Biologics specialty pharmacy is committed to and recognized for its level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses and financial counselors who are familiar with various financial assistance programs and organizations that help patients. This deeply skilled care team works together to develop individualized care plans that address each patient’s unique clinical, financial and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.